Stroke trial aims to prevent second attacks with tailored blood thinners

NCT ID NCT06853535

Recruiting now Disease control Sponsor: Sichuan Provincial People's Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing whether using a blood test to guide antiplatelet therapy can better prevent recurrent strokes in people who have had a mild stroke or transient ischemic attack (TIA). About 5,100 participants will be assigned to either standard clopidogrel or ticagrelor based on their platelet function. The goal is to see if ticagrelor reduces the risk of another stroke within 90 days.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ticagrelor and clopidogrel (antiplatelet drugs)
What this could lead to: If successful, this could provide a more effective antiplatelet strategy for stroke patients who don't respond well to clopidogrel, reducing their risk of another stroke.
What could go wrong: This is a large Phase 3 trial, but it only includes patients with mild strokes or TIAs, so results may not apply to all stroke patients. There is also a risk of bleeding with antiplatelet therapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE ISCHEMIC STROKE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ischemic stroke transient ischemic attack

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE ISCHEMIC STROKE CLOPIDOGREL RESISTANCE

Contacts and locations

Locations

Sichuan Provincial People's Hospital
RECRUITING

Chengdu, Sichuan, 610072, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.